Afatinib demonstrated better efficacy as a first-line, targeted therapy than gefitinib in the Lux-Lung 7 study of patients with advanced EGFR-mutant lung adenocarcinomas [6]. The gene discussed is EGFR; the disease is lung adenocarcinoma.